Fibronostics is a digital healthcare company shaping the future of noninvasive diagnostics for metabolic disease by applying neural network artificial intelligence to blood-based biomarkers.Our first generation products focused on patient identification screening and prognosis of chronic liver disease such as NAFLD/MAFLD and NASH.
The company is incorporated in Delaware with a fully-owned subsidiary in Singapore. We are currently commercially active in North America, Asia, Europe and LATAM.
Fibronostics is a global diagnostics company, shaping the future of noninvasive diagnostics with artificial intelligence that provides algorithm-based solutions in a variety of diagnostic testing areas, focusing on patient identification screening, monitoring and prognosis of liver & kidney disease and other chronic conditions. (HBV, HCV, NAFLD, NASH, and ALD).
The company is incorporated in Delaware with a fully-owned subsidiary in Singapore. We are currently active in North America, Asia, Europe and LATAM.
Interested about our science?
To improve human health by bringing artificial intelligence-based solutions to the diagnosis of major metabolic diseases.